Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q2 FY26 results · Jul–Sep 2025
Onesource Specialty Pharma reported revenue from operations of ₹375.76 crore (up 452.8% from Q2 FY25) and net profit of ₹10.48 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 375.76 | 67.98 | +452.8% | 327.27 | +14.8% |
| Other income | 3.04 | 0.58 | +421.6% | 5.27 | −42.4% |
| Total income | 378.80 | 68.56 | +452.5% | 332.54 | +13.9% |
| Profit before tax | 5.74 | (39.08) | Turned profit | (4.40) | Turned profit |
| Net profit for the period | 10.48 | (39.33) | Turned profit | (0.19) | Turned profit |
| EPS, basic (₹) | 0.92 | (18.82) | not comparable | (0.02) | Turned profit |
| Net margin (%) | 2.8 | -57.8 | -0.1 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 375.19 | 67.98 | +451.9% | 321.01 | +16.9% |
| Other income | 3.04 | 0.58 | +419.9% | 5.25 | −42.2% |
| Total income | 378.22 | 68.56 | +451.6% | 326.27 | +15.9% |
| Profit before tax | 37.10 | (40.02) | Turned profit | 24.82 | +49.5% |
| Net profit for the period | 37.10 | (40.02) | Turned profit | 24.82 | +49.5% |
| EPS, basic (₹) | 3.24 | (19.26) | not comparable | 2.17 | +49.3% |
| Net margin (%) | 9.9 | -58.9 | 7.7 |
Consolidated
- Filed with BSE
- 11 Nov 2025, 17:59 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2025, 17:59 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE